A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2017
At a glance
- Drugs JNJ 61186372 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 04 Jul 2017 Planned number of patients changed from 40 to 90.
- 04 Jul 2017 Planned End Date changed from 19 Oct 2018 to 2 Mar 2020.
- 04 Jul 2017 Planned primary completion date changed from 5 Oct 2018 to 2 Mar 2020.